Shares of Sophiris Bio Inc (NASDAQ:SPHS) ended Thursday session in green amid volatile trading. The shares closed up +0.13 points or 4.48% at $3.03 with 1.86 million shares getting traded. Post opening the session at $2.95, the shares hit an intraday low of $2.83 and an intraday high of $3.08 and the price vacillated in this range throughout the day. The company has a market cap of $84.44 million and the numbers of outstanding shares have been calculated to be 29.12 million shares.
Sophiris Bio Inc (SPHS) on Aug. 9, 2016 announced financial results for the three and six months ended June 30, 2016.
- On June 9, 2016, the Company announced successful results from its completed Phase 2a study of topsalysin in localized prostate cancer.
- On May 12, 2016, the Company announced the engagement Oppenheimer & Co. Inc. as its financial advisor to assist with the evaluation of various strategic options for advancing topsalysin development programs.
- On May 11, 2016, the Company announced the closing of a registered offering in which the Company raised net proceeds of $4.6 million. During June and July, the Company received proceeds of $2.4 million from the exercise of warrants included in this transaction bringing the total proceeds from this offering to $7.0 million.
- On May 7, 2016, the Company presented positive data from its successful Phase 3 clinical trial of topsalysin as a treatment for the symptoms of benign prostatic hyperplasia (“BPH”) as a late breaking poster at the 111th American Urological Association Annual Meeting. A copy of the poster is available on the Company’s website at www.sophirisbio.com.
“2016 is proving to be a transformational year for Sophiris,” stated Randall Woods, president and CEO of Sophiris Bio. “In the past quarter, we completed a Phase 2a proof of concept trial of topsalysin in localized prostate cancer in which topsalysin demonstrated the ability to ablate tumor cells in 50 percent of patients, including two men who experienced complete ablation of their targeted tumor with no evidence of any tumor remaining at 6 months post treatment. We also presented complete results from the Phase 3 BPH study in a late breaking presentation at the AUA 2016 Annual Meeting, demonstrating that topsalysin met the primary endpoint of a reduction in symptom score compared to the vehicle control arm. These two indications represent very large patient populations with very few adequate treatment options, and these clinical results are generating interest from investigators and the medical community. We are currently evaluating our options for moving these programs forward into additional clinical trials.”
Shares of Medtronic PLC (NYSE:MDT) ended Thursday session in green amid volatile trading. The shares closed up +0.37 points or 0.43% at $86.36 with 3.87 million shares getting traded. Post opening the session at $86.48, the shares hit an intraday low of $86.21 and an intraday high of $86.89 and the price vacillated in this range throughout the day. The company has a market cap of $119.34 billion and the numbers of outstanding shares have been calculated to be 1.38 billion shares.
Medtronic PLC (MDT) on Sept. 20, 2016 announced new data, demonstrating safety and efficacy at three years in acute complicated Type B aortic dissection patients treated with the Valiant® Captivia® Thoracic Stent Graft System. Ali Azizzadeh, MD, FACS, University of Texas Health Science Center in Texas presented the new clinical data in a late-breaking trial session at Vascular Interventional Advances (VIVA) 2016.
An acute aortic dissection is a serious condition in which the inner layer of the aorta tears, blood surges through the tear, and causes the inner and middle layers of the aorta to separate. This can result in aorta rupture or malperfusion of the vessels originating from the dissected aorta, leading to high morbidity and mortality. A type B dissection is a tear located in the descending aorta.
“Evidence shows that patients with acute complicated Type B aortic dissections can be safely and effectively treated with thoracic endovascular aortic repair (TEVAR),” said Dr. Azizzadeh. “The Valiant Captivia System continues to produce positive outcomes through three years in a very challenging patient population.”